Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
Currently focused on platform-related queries, elva.AI is the first step in ekincare’s broader roadmap
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Subscribe To Our Newsletter & Stay Updated